• 1
    Kraja A.T., Province M.A., Arnett D., Wagenknecht L., Tang W., Hopkins P.N., Djoussé L., Borecki I.B. (2007) Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutr Metab (Lond) 4: 112.
  • 2
    Kerner A., Avizohar O., Sella R., Bartha P., Zinder O., Markiewicz W., Levy Y., Brook G.J., Aronson D. (2005) Association between elevated liver enzymes and C-reactive protein. Possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 25: 1937.
  • 3
    Loomis W.P., Starnbach M.N. (2002) T cell responses to Chlamydia trachomatis. Curr Opin Microbiol 5: 8791.
  • 4
    Pinar A., Oç M., Akyön Y., Farsak B., Koçyildirim E., Us D., Zorlutuna Y., Tokgözoğlu L., Böke E. (2004) The presence of Chlamydophila pneumoniae, Helicobacter pylori and cytomegalovirus in human atherosclerosis detected by molecular and serological methods. Mikrobiyol Bul 38: 21322.
  • 5
    Haberbosch W., Jantos C. (2000) Chlamydia pneumoniae infection is not an independent risk factor for arterial disease. Herz 25: 7983.
  • 6
    Kalwij S., Macintosh M., Baraitser P. (2010) Screening and treatment of Chlamydia trachomatis infections. BMJ 340: c1915.
  • 7
    Fryer R.H., Schwobe E.P., Woods M.L., Rodgers G.M. (1997) Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med 45: 16874.
  • 8
    Kilic T., Jneid H., Ural E., Oner G., Sahin T., Kozdag G., Kahraman G., Ural D. (2009) Impact of the metabolic syndrome on high-sensitivity C reactive protein levels in patients with acute coronary syndrome. Atherosclerosis 207: 5916.
  • 9
    Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) (2001). JAMA 285: 248697.
  • 10
    Raymond J., Duc-Goiran P., Joundy S., Orfila J., Acar J. (1985) Enzyme-linked immunosorbent assay using three different antigen preparations for detection of antibodies to Chlamydia trachomatis. Eur J Clin Microbiol 4: 46872.
  • 11
    Ossewaarde J.M., De Vries A., Van Den Hoek J.A., Van Loon A.M. (1994) Enzyme immunoassay with enhanced specificity for detection of antibodies to Chlamydia trachomatis. J Clin Microbiol 32: 141926.
  • 12
    Ervin R.B. (2009) Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report 5: 17.
  • 13
    Adegoke O., Adedoyin R., Adebayo R., Bisiriyu L., Salawu A. (2010) Prevalence of metabolic syndrome in a rural community in Nigeria. Metab Syndr Relat Disord 8: 5962.
  • 14
    Gupta R., Deedwania P., Gupta A., Rastogi S., Panwar R., Kothari K. (2004) Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol 97: 25761.
  • 15
    Dean D. (2009) Chlamydia trachomatis today: treatment, detection, immunogenetics and the need for a greater global understanding of chlamydial disease pathogenesis. Drugs Today (Barc) 45(Suppl B): 2531.
  • 16
    Fan Y., Wang S., Yang X. (1999) Chlamydia trachomatis (mouse pneumonitis strain) induces cardiovascular pathology following respiratory tract infection. Infect Immun 67: 614551.
  • 17
    Hatch G., McClarty G. (2004) Chlamydia trachomatis-infection accelerates metabolism of phosphatidylcholine derived from low density lipoprotein but does not affect phosphatidylcholine secretion from hepatocytes. BMC Microbiol 4: 8.
  • 18
    Blessing E., Nagano S., Campbell L., Rosenfeld M., Kuo C. (2000) Effect of Chlamydia trachomatis infection on atherosclerosis in apolipoprotein E-deficient mice. Infect Immun 68: 71957.
  • 19
    Mavrogeni S.M., Spargias K., Kolovou G., Saroglu G., Cokkinos D.V. (2008) Myocardial involvement in a patient with Chlamydia trachomatis infection. J Card Fail 14: 3513.